Quick Answer
Alzamend Neuro, Inc. reported Cash And Cash Equivalents At Carrying Value of $3.95 million for the year ending 2025.
- Alzamend Neuro, Inc. showed an increase of +950.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Alzamend Neuro, Inc.'s annual report (Form 10-K), filed with the SEC on July 22, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $63.1 thousand | Q4 2020: $5.9 thousand | Q1 2021: $40.7 thousand | Q2 2021: $1.93 million | Q3 2021: $15.62 million | Q4 2021: $13.57 million | Q1 2022: $11.79 million | Q3 2022: $11.53 million | Q4 2022: $9.18 million | Q1 2023: $7.38 million | Q3 2023: $1.70 million | Q4 2023: $200.1 thousand | Q1 2024: $282.9 thousand | Q3 2024: $1.19 million | Q4 2024: $4.09 million | Q1 2025: $3.36 million | Q2 2025: $3.95 million | Q3 2025: $5.62 million | Q4 2025: $4.45 million.
- Over the full 7 years of available data (2019 to 2025), Alzamend Neuro, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 9,167.8%.
- Historical annual values: Fiscal year 2025: $3.95 million | Fiscal year 2024: $376.0 thousand | Fiscal year 2023: $5.14 million | Fiscal year 2022: $14.06 million | Fiscal year 2021: $1.93 million | Fiscal year 2020: $90.3 thousand | Fiscal year 2019: $42.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: